tbuckley/cabot-search huggingface dataset:
Asheville, or the Sky-Land.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Polyp Surveillance in Patients With Limited Life Expectancy
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gaseous Metabolism in Newly Born Human Infants
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CAFFEY'S ENIGMA
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biochemistry of Human Cancer
Authors: Henry M. Lemon, Burnham S. Walker, M. Moira Davison Reynolds, Herbert H. Wotiz
Journal: New England Journal of Medicine (1954)

Alteration of Urinary Constituents Steroids. The relation of urinary steroids to neoplastic disease was first systematically explored by Dobriner,242 , 243 whose investigations stimulated many other laboratories to engage in the problem and to improve the methods of assay. The stereospecificity of urinary adrenal steroid metabolites was a matter of debate until Dorfman and his colleagues244 obtained stereochemical correlation of isomers at the 3-carbon and 5-carbon positions. This may provide an insight into the nature of enzymes involved in steroid metabolism and contributes to better chemical procedures differentiating urinary metabolites arising from adrenal cancer and those originating from adrenal hyperplasia. The application . . .
Regulation of Iron Metabolism: Translational Effects Medicated by Iron, Heme, and Cytokines
Authors: D. P. Mascotti
Journal: Annual Review of Nutrition (1995)

The objective of this review is to provide an overview of intermittent fasting regimens, summarize the evidence on the health benefits of intermittent fasting, and discuss physiological mechanisms by which intermittent fasting might lead to improved ...Read More
Liver failure in children with hepatitis A
Authors: D Debray, P Cullufi, D Devictor, M Fabre, O Bernard
Journal: Hepatology (1997)

There have been very few reports dealing with liver failure related to hepatitis A in children. Moreover, the criteria usually used for selecting patients with fulminant hepatitis A for liver transplantation have not been evaluated in children. Therefore, the current study was conducted retrospectively in a single French urban pediatric liver transplantation center to serve as a reminder of the potential severity of hepatits A in children and to identify predictors of outcome. Children were selected by chart review using a data base system and were grouped according to outcome for analyses purposes. Over a 15-year period, 24 children with hepatitis A showed evidence of liver failure, including 6 children who did not develop hepatic encephalopathy, 7 children in whom encephalopathy occurred but resolved spontaneously, and 11 children in whom death or liver transplantation was the outcome. The mean age at onset was 6.5 years. Those with the most rapid onset of liver failure from onset of jaundice had the best chance of recovery without developing encephalopathy. Otherwise, no predictive factors of outcome were found at onset of liver failure. Among the 18 children who developed encephalopathy, the best early prognostic indicator of a poor outcome irrespective of the grade of encephalopathy, appeared to be a prothrombin time level below 21% of normal combined with a serum bilirubin level above 400 μmol/L. Therefore, these two prognostic indicators may be helpful in deciding liver transplantation in children with hepatitis A-induced fulminant liver failure.
Age-sex registers as a screening tool for general practice: size of the wrong address problem.
Authors: A J Silman
Journal: BMJ (1984)

Age-sex registers were compiled and updated for the east London general practices participating in a screening study for hypertension. Of 1435 addresses in the registers of two practices that were checked, 228 (16%) were incorrect, according to the return by the post office of the screening invitations and checking the addresses of the non-responders using telephone directories and the medical records. The non-responders to the screening invitation for whom a new address was not found, were visited at the address as recorded on the age-sex register. This showed that the true address error rate from the original age-sex registers was 26% and thus substantially greater than that calculated from returned letters. It is concluded that the non-acceptance rate of screening in general practice might be exaggerated as a result of the lack of a correct address for a substantial proportion of the patients on a general practice list.
Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
Authors: P Marcellin
Journal: Hepatology (1991)

We have conducted a multicenter randomized controlled trial comparing two doses of recombinant human α-interferon for efficacy in 60 patients with chronic non-A, non-B hepatitis. The source of infection appeared to be transfusion in 30 patients, intravenous drug abuse in 16 patients and was unknown in 14 patients. Patients were randomly assigned to no treatment or to treatment with either 1 or 3 MU of α-interferon given three times a week for 24 wk. Forty-five patients (75%) were positive for antibody to hepatitis C virus. During the 24-wk treatment period, mean serum ALT levels decreased in both treatment groups, but the decrease was statistically significant only in the 3 MU group. However, at 24 wk, the proportion of patients with normal ALT levels was similar in the 3 MU group (39%) and the 1 MU group (45%), and both were significantly higher than in controls (0%). Repeat liver biopsy specimens showed a significant decrease in the severity of histological changes in the 3 MU group but not in the 1 MU group or in controls. Responses to α-interferon did not correlate with patients' age, gender, source of infection, pretreatment serum ALT, presence of anti-hepatitis C virus or cirrhosis. After treatment, the mean ALT levels rose in both treated groups. The proportion of patients with normal ALT levels at wk 48 was 28% in the 3 MU group and 20% in the 1 MU group. In conclusion, a dose of 3 MU was superior to 1 MU of α-interferon given three times weekly for 24 wk in inducing improvements in serum ALT levels and liver histological examinations. Relapse in disease activity occurred in approximately half of the responders when interferon was stopped. The response to α-interferon did not correlate with the source of infection or with the presence or absence of anti-hepatitis C virus. (HEPATOLOGY 1991;13:393–397.)
Multiple-dose pharmacokinetics and safety of CC-5013 in 15 multiple myeloma patients
Authors: A. Wu, M. R. Scheffler
Journal: Journal of Clinical Oncology (2004)

2056 Background: CC-5013 is a member of a novel class of pharmaceutical compounds, known as immunomodulatory drugs (IMiDs™), which modulate cytokines, induce apoptosis and inhibit angiogenesis. CC-5013 has demonstrated activitiy against multiple myeloma (MM) as well as shown potential in Myelodysplastic Syndromes and solid tumors. The pharmacokinetic profile of multiple doses of CC–5013 was assessed during an ongoing safety and efficacy trial in MM patients. Methods: 15 MM patients (age≥18 yrs.) were enrolled in this open-label, ascending, multiple-dose study (5, 10, 25 or 50mg QD). Blood samples were taken for LC-MS/MS analysis of plasma CC-5013 at: pre-dose, 0.25, 0.5, 0.75, 1, 2, 2.5, 3, 4, 6, 10, 12, 18, and 24 hours post-dose, on both day 1 and 28. Results: PK parameters are summarized in the table below: No CC-5013 dose-limiting toxicity was observed at any dose level within the first 28 days. Conclusions: 1) Absorption was rapid on both day 1 and 28, with tmax ranging from 0.7–2.0 hours at all dose levels, 2) Plasma CC5013 declined in a monophasic manner with elimination half-life ranging from 2.8–6.1 hours on both day 1 and 28 at all four doses, 4) No plasma accumulation was observed upon multiple dosing, and 5) Plasma exposures (AUC0-τ, Cmax) are dose-proportional over the range of 5–50mg). 3) Daily oral doses of CC-5013 up to 50 mg produced no dose-limiting toxicity within the first 28 days. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene Corp. Celgene Corp. Celgene Corp.
Fact or Fiction?
Authors: Renee Twombly
Journal: Annals of Internal Medicine (1996)

Letters1 June 1996Fact or Fiction?Renee TwomblyRenee TwomblyNews Office, Duke University Medical Center, Durham, NC 27710Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-11-199606010-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:It seems amazing that Annals would publish “The Breakthrough” [1], which decries hype when the piece itself is pure fiction. The author, Dr. David Pisetsky, is not a cardiologist and has never reported a medical breakthrough in Heart. There is no public information officer named Jennifer Richman, nor, I suspect, a patient named Roy Carver. The story was just that—a story, not real.The problem is that, at the end of the piece, Dr. Pisetsky identifies himself correctly, as a physician at Duke University Medical Center. His fictionalized account of “public relations” swirls around a hospital called ...REFERENCE1. Pisetsky DS. The breakthrough. Ann Intern Med. 1996; 124:345-7. Google Scholar Author, Article, and Disclosure InformationAuthors: Renee TwomblyAffiliations: News Office, Duke University Medical Center, Durham, NC 27710 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1996Volume 124, Issue 11Page: 1016-1017KeywordsCrimeFearHeart ePublished: 15 August 2000 Issue Published: 1 June 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Proving Planck wrong. A perspective on the new biotechnology
Authors: H. I. Miller
Journal: JAMA (1987)

An important scientific innovation rarely makes its way by gradually winning over and converting its opponents.... What does happen is that its opponents gradually die out and that the growing generation is familiarized with the idea from the beginning. Max Planck, 1936 ALTHOUGH Nobel laureate Planck made this observation in another context, it may be applicable to "new" biotechnology. This would be unfortunate, because new biotechnology has just begun to fulfill its promise. The trickle of products undergoing testing has become a flood, and the numbers of governmental approvals of products are increasing exponentially. However, some recent government approvals and industry's proposals to test a variety of products, especially those that involve live organisms outside a manufacturing facility, have received mixed responses from an uncertain popular press and public. A very few vocal, well-organized opponents of biotechnology have confused the issue by mixing facts with myths. One myth is that
Medicine in the USA: historical vignettes. VI. Medical education: the AMA surveys the problems
Authors: L. S. King
Journal: JAMA (1982)

When the National Medical Convention met in 1846, a major concern was the low state of medical education. "We believe from the complaints which spring from almost every quarter, that lamentable deficiencies do exist, and that these deficiencies should be corrected."<sup>1</sup>The convention then adopted the time-honored mode of appointing committees to analyze specific aspects and make recommendations. To understand the proffered comments and recommendations, we must have a broad view of the problems and of the way these developed. The National Medical Association—to become the American Medical Association the following year—came into existence during a transitional period in American culture. Old modes of medical education, adequate for an earlier period, could no longer adapt satisfactorily to changing needs. The older apprentice training had to be replaced by something better, but new procedures would develop slowly and painfully, inevitably with many false turnings. In, say, 1800, the ideal apprenticeship
Abstract 5065: Fine-mapping the <i>HOXB</i> region detects common variants tagging a rare coding allele: Evidence for synthetic association in prostate cancer
Authors: Zsofia Kote-Jarai, Edward Saunders, Tokhir Dadaev, Daniel Leongamornlert, Sarah Jugurnauth-Little, Malgorzata Tymrakiewicz, Koveela Govindasami, Fredrik Wiklund, Ali Amin Al Olama, Sara Benlloch, Douglas Easton, Keneth Muir, Rosalind Eeles
Journal: Cancer Research (2014)

Abstract The HOXB13 gene has been implicated in prostate cancer susceptibility. We performed a high resolution fine-mapping analysis to comprehensively evaluate the association between common genetic variation across the HOXB genetic locus at 17q21 and PrCa risk. This involved genotyping 700 SNPs using a custom Illumina iSelect array (iCOGS) followed by imputation of 3195 SNPs in 20,440 prostate cancer cases and 21,469 controls in The PRACTICAL consortium. We identified a cluster of highly correlated common variants situated within or closely upstream of HOXB13 that were significantly associated with prostate cancer risk, described by rs117576373, OR 1.30, P = 2.62×10-14. Additional genotyping, conditional regression and haplotype analyses indicated that the newly identified common variants tag a rare, partially correlated coding variant in the HOXB13 gene, G84E, rs138213197, which has been identified recently as a moderate penetrance prostate cancer susceptibility allele. The potential for GWAS associations detected through common SNPs to be driven by rare causal variants with higher relative risks has long been proposed; however, to our knowledge this is the first experimental evidence for this phenomenon of synthetic association contributing to cancer susceptibility. Citation Format: Zsofia Kote-Jarai, Edward Saunders, Tokhir Dadaev, Daniel Leongamornlert, Sarah Jugurnauth-Little, Malgorzata Tymrakiewicz, Koveela Govindasami, Fredrik Wiklund, Ali Amin Al Olama, Sara Benlloch, The PRACTICAL Consortium, Douglas Easton, Keneth Muir, Rosalind Eeles. Fine-mapping the HOXB region detects common variants tagging a rare coding allele: Evidence for synthetic association in prostate cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5065. doi:10.1158/1538-7445.AM2014-5065
Syringe Dispensers
Authors: Rebecca Voelker
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smoking: Health Effects and Control
Authors: Jonathan E. Fielding
Journal: New England Journal of Medicine (1985)

The Changing CigaretteBetween 1954 and 1983 the introduction of filters and low-tar cigarettes in response to consumer demand led to a decline in the average tar content of a cigarette in the United States of more than two thirds — from 38 mg to below 12 mg per cigarette — and the average nicotine content decreased from 2.3 mg to slightly below 1.2 mg.88 89 90 Since their introduction to the U.S. cigarette market in the late 1960s and the early 1970s, low-tar-and-nicotine cigarettes (defined as having less than 15 mg of tar per cigarette) have rapidly increased their market share . . .
Hepatic Effects of Phthalate Esters
Authors: Prahlad K. Seth
Journal: Environmental Health Perspectives (1982)

Di(2-ethylhexyl) phthalate (DEHP), a commonly used plasticizer and microchemical environmental pollutant, produces subtle changes in hepatic function as judged by increase in liver weight and morphological and biochemical alterations. It can modify the biological response of drugs and other xenobiotics. Such interactions appear to occur at the pharmacokinetic phase, as DEHP was found to alter the activity of microsomal drug-metabolizing enzymes and ethanol metabolism. DEHP produced a time- and route-dependent effect on the hepatic cytochrome P-450 contents and activity of aminopyrine N-demethylase, aniline hydroxylase, alcohol dehydrogenase and high and low Km aldehyde dehydrogenases when given orally or intraperitoneally. Under in vitro conditions, DEHP produced no effect on the activity of aminopyrine N-demethylase or aniline hydroxylase, while mono(2-ethylhexyl) phthalate (MEHP) and 2-ethylhexanol (2-EH) significantly inhibited their activity at concentrations ranging from 2.5 to 15.0 mM. Activity of aminopyrine N-demethylase and aniline hydroxylase was also inhibited by dimethyl phthalate (DMP) and dibutyl phthalate (DBP) after a single oral administration. In view of the possibility of the human exposure to phthalates and other xenobiotics simultaneously, these observations are of great significance.
Massachusetts Medical Society
Authors: Alfred Weller, John Figgis Jewett
Journal: New England Journal of Medicine (1961)

COMMITTEE ON MATERNAL AND PERINATAL WELFARENeonatal Death Due to Placental InsufficiencyA twenty-five-year-old gravida 1 was examined first at eight weeks and thereafter at monthly intervals until the third trimester, when she was seen more often, visits being made at weekly or shorter intervals from thirty-six to forty-four weeks. Blood pressures and urinalyses were within normal limits throughout, but she gained 19.3 kg. (42 1/2 pounds) without overt edema. Uterine size was always consistent with the dates. Because of an unengaged vertex at forty weeks x-ray pelvimetry was ordered, confirming pelvic adequacy. During the last three weeks amniotomy was . . .